ArticleThe American journal of case reports2025
Renal Cell Carcinoma with Fibromyomatous Stroma: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Renal cell carcinoma with fibromyomatous stroma (RCC FMS), which includes positivity for elongin C/transcription elongation factor B mutation, is a relatively new World Health Organization (WHO) entity in the classification of renal tumors, with less than 20 reported cases in total. Clinically, the tumors present as solitary renal cortical masses, pelvic pain, or hematuria. These tumors lack VHL mutations, hypermethylation, or loss of heterozygosity at 3p, which are characteristics of clear cell renal cell carcinoma. CASE REPORT We report a case of renal neoplasm in a 59-year-old male patient who initially presented with hematuria. Radiological examination showed a 2-cm rounded mass located at the upper pole of the right kidney. Histological examination revealed a renal neoplasm formed of nests, solid areas, and alveolar arrangement of WHO/International Society of Urological Pathology grade 1 epithelioid cells, transected by thick fibromuscular bands. The tumor cells had voluminous clear cytoplasm, well-defined cell borders, and central, rounded, non-atypical nuclei. Immunohistochemically, the tumor was positive for CK7, AMCR, PAX-8, and CD10, while the stromal muscle bundles were positive for smooth muscle actin and vimentin. All of the mentioned features are characteristic of RCC FMS. CONCLUSIONS This case report presents RCC FMS as a new subtype of RCC, characterized by unique morphologic, immunohistochemical, and molecular features that set it apart from more prevalent types of renal epithelial tumors, such as clear cell RCC, papillary RCC, and clear cell papillary RCC. Due to its rarity and good prognosis compared with other renal tumors, attention should be paid when dealing with renal epithelial tumors that exhibit the usual features of other epithelial tumors but with abundant fibromyomatous stroma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.